In this issue is published the first economic analysis of another landmark clinical trial.
Jonsson et a/.' 11 report an analysis of the cost-effectiveness of simvastatin as used in the Scandinavian Simvastatin Survival Study (4S). This type of analysis should represent a major advance over previous economic analyses which have been based on epidemiological models rather than randomized controlled trials'
The authors' main conclusion is that the incremental, discounted, cost per life year gained (LYG) is SEK 56 400 (£5500). We believe that this finding must, however, be treated with caution for two important reasons. Firstly, this scenario projects an additional life expectancy of 10 years for patients alive at the end of the 5-5 years of the trial although further treatment costs are not added during this additional period. Extrapolation of life beyond the end of a trial is fraught with difficulty and can greatly alter the incremental cost effectiveness ratio. The within-trial cost per LYG for 4S is approximately SEK 250 750 (£24 500). It is instructive to compare these within-trial and extrapolated lifetime cost effectiveness ratios from 4S with those from the economic analysis of the Survival And Ventricular Enlargement (SAVE) study published in the May issue' 41 . For SAVE, the within-trial cost per LYG was DFL22 887 (£8820) whereas the lifetime cost per LYG was DFL 15 799 (£6088). Clearly the improvement in the cost effectiveness ratio for 4S (£24 500 to £5500) is much greater than for SAVE as a result of post trial extrapolation of life expectancy.
Secondly, the authors base scenario does not consider the cost of monitoring treatment i.e. measurement of cholesterol, checking liver enzymes etc. These extra costs are included in the sensitivity analyses and increase the cost per LYG from £5502 to £9376, based on lifetime projection.
A number of other considerations are important. The authors do not report a sensitivity analysis for the cost of treatment although the costeffectiveness ratio will undoubtedly be sensitive (perhaps most sensitive) to the cost of the drug used to lower cholesterol. With our current understanding of cholesterol lowering therapy, the cost of use when comparing treatments should probably be cost per millimole reduction in cholesterol concentration.
A sensitivity analysis examining the cost effectiveness of simvastatin in survivors of myocardial infarction vs those with angina only (who made up approximately one fifth of the 4S patients) would also have been of great interest, not least to health care purchasers and providers. Because the absolute risk of the former patients was much higher, the clinical benefit from simvastatin in these patients was also much greater. Simvastatin treatment resulted in 9-6 fewer major coronary events per 100 patients treated with a previous myocardial infarction compared to 45 fewer in those with angina' 51 . Although complex, the issue of indirect costs (e.g. those related to employment, sick leave, production losses etc) should be mentioned. In two previous studies from Sweden, dealing with myocardial infarction, indirect costs have been found to be of considerable importance, accounting for at least as much as the direct costs of treatment' 6 ' 71 . Indeed, it is difficult to sustain the argument that indirect costs can be dismissed as transfer payments within society, given that, ultimately, all costs can be reduced to transfer payments within society.
Accepting these caveats, how does the cost effectiveness of simvastatin in 4S compare with other interventions? Perhaps the easiest comparisons to make are those with other economic evaluations from the Stockholm School' . Although this was a 'primary' prevention trial, the patients recruited were at high risk. The cost per LYG in STOP was SEK 5000-15000 (1991 prices). Anti-hypertensive therapy in younger patients or in those with milder hypertension (i.e. lower risk patients) is much less costeffective e.g. SEK 500 000 (£49 000) for a 40-year-old man with a diastolic blood pressure of 95 mmHg' 91 . The most relevant, but more difficult, comparison is with that of captopril in the SAVE study 0195-668X/96/070974+13 SI8.00/0i.e. another 'secondary' prevention intervention. Two economic analyses of the SAVE study are now available but have been conducted in different health care systems (the Netherlands and the USA) [4 -10] . Despite this, both estimate the lifetime cost per LYG with captopril to be approximately £6000 (nearly £9000 per LYG, within trial, in the Dutch analysis). Apart from methodological issues, the greater within-trial cost in 4S (£24 500) compared to SAVE must, in part, reflect the clinical benefit of the two interventions in the two post myocardial populations. In SAVE, there were 12 fewer deaths, nine fewer myocardial infarction's, 16 fewer cases of heart failure and 10 fewer revascularisations per 1000 patient years of treatment; the equivalent figures for 4S were 6, 12,4 and 11. These events prevented represent the potential to offset the cost of the treatment intervention. Stress-induced ST-segment elevation after a recent myocardial infarction: myocardial necrosis, viability or both?
See page 1008 for the article to which this Editorial refers
The assessment of residual myocardial ischaemia and viability is important for the management of patients after acute myocardial infarction. Recent data have inferred the value of dobutamine stress echocardiography for that purpose' 1 >2) . ST-segment elevation is frequently induced by dobutamine or exercise stress testing in these patients. Therefore, it is important to evaluate the functional significance of this electrocardiographical finding and its relation to the presence of jeopardized myocardium in the infarct region.
While available data agree on the specificity of stress-induced ST-segment elevation for ischaemia in patients without previous myocardial infarction' 3 ' 41 , the significance of these findings in patients with myocardial infarction is controversial' Margonato et alP^ found reversible defects on exercise thallium scintigraphy in 16 of 17 patients with exercise-induced ST-segment elevation after recent myocardial infarction. However, there was no control group without ST-segment elevation to exclude the theory that the high predictive value of ST-segment elevation for ischaemia is related to the selection of patients with high likelihood of manifesting
